CD8A and non-small cell lung carcinoma: (45) demonstrated in a humanized mouse model of non-small cell lung cancer (NSCLC) that the LDH inhibitor oxamate may enhance the therapeutic effect of pembrolizumab by a mechanism mainly associated with an increase in activated CD8 + T cells in tumors.